经尿道钬激光前列腺剜除术治疗大体积良性前列腺增生

目的：评价经尿道钬激光前列腺剜除术（HoLEP）治疗大体积良性前列腺增生（BPH）的价值。方法：BPH患者60例，前列腺重量均〉100g，分为HoLEP组（n=32）和耻骨上经膀胱前列腺切除术组（n=28）。比较两组手术时间、术中出血量和术后膀胱冲洗时间、导尿管留置时间、住院时间；术后3个月随访，比较两组患者IPSS、生活质量评分（QOL）、最大尿流率（Qmax）、剩余尿量（PVR）等指标的变化。结果：HoLEP组与耻骨上经膀胱前列腺切除术组比较手术时间有所延长（P〈0．01），但术中出血量减少（P〈0．01），膀胱冲洗时间、导尿管留置时间、术后住院时间明显缩短（P〈0．01）。术后3个月，两组IPSS、QOL、Qmax、PVR较自身术前显著改善（P〈0．01），组间比较差异无显著性（P〉0．05）。结论：HoLEP治疗大体积BPH具有与开放性前列腺切除术相似的疗效，同时手术安全性高、患者痛苦小、术后恢复快，是一种更适合于大体积BPH治疗的手术方式。     

经尿道钬激光前列腺剜除术治疗良性前列腺增生

目的 :评价经尿道钬激光前列腺剜除和前列腺组织粉碎术治疗良性前列腺增生 (BPH)的临床效果。　方法 :应用 10 0W钬激光器和组织粉碎器对 35例BPH病人实施经尿道钬激光剜除和前列腺组织粉碎术治疗。　结果 :本组 35例手术均获成功。手术时间 30～ 180min ,平均 (6 0 .0± 2 3.2 )min。获得前列腺组织 10～ 5 6g ,平均(31± 9) g ,术后留置导尿管时间 2 0h～ 4d ,平均1.5d。无术中术后输血病例。组织病理学诊断均为BPH。 32例获随访 ,术后 3个月随访国际前列腺症状评分 (IPSS)由 (2 4.0± 6 .2 )分降至 (5 .6± 3.6 )分 (P <0 .0 0 1)。最大尿流率 (Qmax)由 (8.5± 3.9)ml/s上升至 (2 2 .0± 7.2 )ml/s(P <0 .0 0 1) ,残余尿由 (138± 12 5 )ml减少到 (2 1± 15 )ml,未发生严重并发症。　结论 :钬激光前列腺剜除术是治疗BPH的有效微创方法 ,术中术后出血少 ,能够完整剜除增生的前列腺组织。留置导尿管时间短 ,临床症状改善明显。     

钬激光前列腺剜除术后尿道功能障碍的康复效果

目的观察钬激光前列腺剜除术后尿道功能障碍的康复效果。方法 84例前列腺增生病人,根据入院顺序编号,采用随机数字表法分为观察组和对照组,各42例;观察组采取钬激光前列腺剜除术治疗,对照组采取前列腺电切术治疗;随访3个月,比较两组围术期各项信息、手术并发症发生率,主观症状包括国际前列腺症状评分(IPSS评分),生活质量评分(QOL评分),勃起功能专项评分(IIEF-EF评分),客观症状包括最大尿流率(Qmax),残余尿量(PVR),最大逼尿肌压力(MDP)等改善情况。结果两组手术时间比较,差异无统计学意义(P0.05);观察组术中出血量明显少于对照组,膀胱冲洗时间、尿管留置时间、住院时间均明显短于对照组,差异均有统计学意义(P0.05);两组病人在术后1个月和3个月均获得随访,观察组手术并发症发生率为19.05%,明显低于对照组的40.48%,差异有统计学意义(P0.05);两组术后主观症状和客观症状均较术前明显改善,其中观察组术后1个月的IPSS评分为(7.92±1.47)分,低于对照组的(12.45±3.56)分,QOL评分为(1.26±0.53)分,低于对照组的(2.35±0.47)分,IIEF-EF评分为(18.41±5.62)分,高于对照组的(15.04±4.97)分,Qmax为(16.47±3.57)ml/s,大于对照组的(12.58±3.61)ml/s,PVR为(5.91±1.19)ml/s,少于对照组的(9.87±2.24)ml/s,MDP为(47.15±4.85)cmH_2O,大于对照组的(40.05±4.71)cmH_2O,差异均有统计学意义(P0.05);两组术后3个月的IPSS评分、QOL评分、IIEF-EF评分、Qmax、PVR和MDP比较,差异均无统计学意义(P0.05)。结论前列腺增生病人钬激光剜除术后尿道功能障碍的康复效果确切、可靠,具有术后排尿、控尿和性功能恢复快等优点。     

经尿道钬激光前列腺剜除术治疗大体积良性前列腺增生

目的:评价经尿道钬激光前列腺剜除术(HoLEP)治疗大体积良性前列腺增生(BPH)的价值。方法:BPH患者60例,前列腺重量均>100g,分为HoLEP组(n=32)和耻骨上经膀胱前列腺切除术组(n=28),比较两组手术时间、术中出血量和术后膀胱冲洗时间、导尿管留置时间、住院时间;术后3个月随访,比较两组患者IPSS、生活质量评分(QOL)、最大尿流率(Qmax)、剩余尿量(PVR)等指标的变化。结果:HoLEP组与耻骨上经膀胱前列腺切除术组比较手术时间有所延长(P<0.01),但术中出血量减少(P<0.01),膀胱冲洗时间、导尿管留置时间、术后住院时间明显缩短(P<0.01)。术后3个月,两组IPSS、QOL、Qmax、PVR较自身术前显著改善(P<0.01),组间比较差异无显著性(P>0.05)。结论:HoLEP治疗大体积BPH具有与开放性前列腺切除术相似的疗效,同时手术安全性高、患者痛苦小、术后恢复快,是一种更适合于大体积BPH治疗的手术方式。     

经尿道钬激光前列腺剜除术治疗前列腺增生

目的评价经尿道钬激光前列腺剜除和前列腺组织粉碎术治疗良性前列腺增生（BPH）的临床效果,探讨手术操作技巧及并发症的预防。方法应用100 W钬激光器和组织粉碎器对45例BPH患者实施经尿道钬激光前列腺剜除（HoLEP）和组织粉碎术。术前国际前列腺症状评分（IPSS）为15-32分,平均24.0分,最大尿流率（Qmax）为4-15 mL/s,平均8.4 mL/s,膀胱残余尿为60-246 mL,平均115 mL。结果41例行HoLEP手术成功。手术时间50-200 min,平均105 min,获得前列腺组织30-85 g,平均48.6 g,其中输血5例,膀胱黏膜或膀胱壁损伤5例,尿失禁1例,尿道狭窄3例。保留导尿时间3-7 d,平均4.3 d。术后35例获随访3个月,IPSS降至3-10分,平均5.2分（P〈0.01）,Qmax升至18-25 mL/s,平均22.4 mL/s（P〈0.01）,膀胱残余尿为0-68 mL,平均26 mL（P〈0.01）。结论经尿道钬激光剜除前列腺组织损伤小,术中出血少,并发症少,疗效可靠。HoLEP学习曲线较长,应注意手术技巧的掌握,减少并发症的发生。     

经尿道钬激光前列腺剜除术治疗良性前列腺增生的学习曲线研究

目的:总结并探讨连续实施经尿道钬激光前列腺剜除术(HoLEP)治疗良性前列腺增生(BPH)的安全性、效率及学习曲线。方法:回顾性分析2017年5月～2018年6月我院1位熟练掌握经尿道前列腺电切术(TURP)的泌尿外科医师采用HoLEP治疗99例BPH患者的临床资料。按手术先后顺序,以连续的每33例患者为一组分为A、B、C三组,记录并对比手术前后国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(Q_(max)),对比前列腺体积、手术时间、剜除效率、尿管留置时间、术后尿失禁、术后尿道狭窄情况及术后膀胱颈挛缩情况。结果:三组患者手术时间、剜除效率、术后尿管留置时间比较差异均有统计学意义(P0.05)。A组平均手术时间(97.03±18.09) min,B组平均手术时间(83.00±19.12) min,C组平均手术时间(64.72±7.37) min。A组平均剜除效率(0.71±0.15) mL/min,B组平均剜除效率(1.06±0.25) mL/min,C组平均剜除效率(1.22±0.23) mL/min。A组平均尿管留置时间(4.55±0.56) d,B组平均尿管留置时间(4.03±0.65) d,C组平均尿管留置时间(3.21±0.49) d。三组手术前后IPSS、QOL、Q_(max)、血红蛋白(Hb)下降值比较差异无统计学意义。术后尿失禁发生27例,主要发生于A、B组,均于术后3个月内恢复。中转TURP共5例,主要出现在A组,膀胱损伤1例发生于A组。结论:HoLEP治疗BPH效果确切,通过33例可掌握该手术,66例后手术技术进入比较稳定的平台期,手术效率及安全性显著提高,初学者宜选取前列腺体积60 mL病例实施手术。     

经尿道前列腺钬激光剜除术治疗良性前列腺增生效果分析

目的 探讨经尿道前列腺钬激光剜除术(HoLEP)治疗良性前列腺增生(BPH)的安全性和临床效果.方法 回顾性分析周口永兴医院泌尿外科于2020-01—2021-04收治的84例BPH患者的临床资料.分为HoLEP组(43例)和经尿道等离子前列腺切除术组(PKRP组,41例).比较2组术中情况和术后临床指标,统计并发症发...     

经尿道前列腺钬激光剜除术与经尿道前列腺电切术治疗良性前列腺增生的疗效比较

目的 探讨经尿道前列腺钬激光剜除术(homium laser enucleation of the prostate,HOLEP)和经尿道前列腺电切术(transurethrue resection of prostate,TURP)治疗良性前列腺增生(benign prostatic hyperplasia,BPH)...     

经尿道钬激光前列腺剜除术治疗良性前列腺增生症临床价值研究

目的 探讨经尿道钬激光前列腺剜除术(HoLEP)对良性前列腺增生(BPH)患者的临床应用价值.方法 回顾性分析2017-11—2019-09内黄县中医院泌尿外科行手术治疗的80例BPH患者的临床资料.根据手术方式分为HoLEP组和经尿道前列腺电切组(TURP组),每组40例.比较2组患者的基线资料、术中情况,以及术后临...     

良性前列腺增生经尿道钬激光前列腺剜除术的围术期整体护理

目的探讨良性前列腺增生(BPH)经尿道钬激光前列腺剜除术的围术期整体护理方法。方法选取2017-10—2019-04间接受经尿道钬激光前列腺剜除术治疗的40例BPH患者,实施术前针对性心理护理、完善各项手术准备,术后严密观察病情变化、做好管道护理和防治各种并发症,以及加强出院时的健康宣教等整体护理措施。结果40例患者手术过程顺利。术中出血量(89.23±10.30)mL,手术时间(69.31±8.30)min,术后膀胱冲洗时间(11.27±1.82)h。术后出现2例短暂性尿失禁,经对症处理后痊愈。未发生膀胱穿孔、电切综合征和尿道狭窄等其他并发症。拔除尿管后均能自行排尿,排尿障碍明显改善。住院时间(9.58±1.42)d。患者术后均获6个月随访,其间无1例复发。结论对接受经尿道钬激光前列腺剜除术的BPH患者,围术期加强心理、管道、并发症的观察和预防,以及健康教育等整体护理,可提高手术成功率,降低术后并发症发生率,促进患者早期康复。     

Management of prostate cancer after holmium laser enucleation of the prostate

IntroductionHolmium laser enucleation of the prostate (HoLEP) is effective in treating lower urinary tract symptoms from prostatic disease. We investigate the role of HoLEP in the management of patients with benign prostatic hypertrophy (BPH) and prostate cancer (CaP).MethodsRetrospective review of data regarding all patients undergoing HoLEP at a single institution was performed. Pre- and postoperative PSA, multiparametric MRI, and pathology results were analyzed for those with CaP identified prior to or incidentally at HoLEP.ResultsFrom February 2016 to February 2020, 201 patients underwent HoLEP. Twelve patients had CaP diagnosed before HoLEP: 6 patients with GG1 are on active surveillance (AS), 3 of 4 intermediate-risk patients are on AS and 1 received treatment for disease progression, and both high-risk CaP patients achieved symptomatic benefit from HoLEP and are receiving systemic therapy for CaP. Twenty-one patients (11.1%) with incidentally detected CaP at HoLEP remain on AS or watchful waiting based on clinical scenario.ConclusionScreening for CaP in HoLEP candidates with PSA and MRI is recommended given that >10% will have incidental CaP. After HoLEP for BPH/LUTS, patients with CaP can be surveilled with PSA and/or MRI. Further investigation is warranted to determine the durability of success of these approaches.     

前列腺剜除术后排尿功能恢复的相关因素及快速康复干预分析

目的探究影响经尿道钬激光前列腺剜除术（HoLEP）术后排尿功能恢复的相关因素及对快速康复干预的分析。 方法回顾性分析2018年10月至2019年10月,来我院行HoLEP的患者120例,按照术后排尿功能恢复时间,将≤2周的分为A组,共52例,>2周的分为B组,共68例,探究影响术后排尿功能恢复的相关因素,分析快速康复干预措施。另选取2019年10月至2020年3月来我院行HoLEP的患者62例,随机分成观察组及对照组,各31例,观察组采取快速康复干预,对照组采取常规护理,比较两组术后相关资料。 结果单因素分析显示,A组与B组患者在括约肌是否受损、膀胱功能障碍、术后出血、尿路感染等方面差异有统计学意义（P<0.05）,两组患者在吸烟、饮酒、术前IPSS评分方面差异无统计学意义（P>0.05）;多因素分析显示括约肌损伤、膀胱功能障碍、术后出血、尿路感染是影响经尿道HoLEP术后排尿功能恢复的独立危险因素。观察组的下床活动时间、排气时间、进食时间、留置导管时间、术后住院时间均低于对照组（P<0.05）;术后,观察组及对照组在尿路感染、暂时性尿失禁、术后尿潴留、尿道狭窄发生情况比较差异无统计学意义（P>0.05）;术后1周,观察组RUV低于对照组,Qmax高于对照组（P<0.05）。 结论围手术期进行一系列快速康复干预措施,能帮助患者术后快速恢复排尿功能,提高其生活质量。     

Incidental prostate cancer revisited: Early outcomes after holmium laser enucleation of the prostate

Incidental prostate cancer (PCa) after treatment of benign prostate hyperplasia (BPH) is becoming less common. This is a result of the changing patterns of BPH treatment. The purpose of the present research was to re‐examine the clinical outcomes and importance of cT1a and cT1b PCa in a contemporary cohort after holmium laser enucleation of the prostate (HoLEP). All patients with newly diagnosed PCa after HoLEP were retrospectively identified. Pre‐ and postoperative prostate‐specific antigen (PSA), biopsy history, pathological features and disease progression were examined. Patients were matched to a control group with benign pathology for outcome comparisons. The database consisted of 240 consecutive patients, aged 52–90 years with prostate sizes from 25 to 375 cm³. A total of 28 patients were identified with incidental PCa (14 cT1a and 14 cT1b). Median follow up was 11 months and 13 months for cT1a and cT1b, respectively. Hospitalization time, catheterization time, complications and functional outcomes were similar. Three patients with cT1b required additional treatment as a result of PSA progression. All other cancers are being closely followed. The functional benefits of HoLEP are well established. The incidental PCa detection rate of 11.7% shows the potential benefit of pathological analysis. Just 10.7% of these patients received additional treatment, but this might be significant as these patients would otherwise go untreated. The impact on disease‐specific survival and progression requires a longer follow up.     

Current status of holmium laser enucleation of the prostate

There are several options for the surgical management of benign prostatic hyperplasia representatively from transurethral resection of the prostate. Holmium laser enucleation of the prostate is one of those options, and many institutions and urologists have initiated this technique, and most of them have accomplished better outcomes compared with transurethral resection of the prostate. In contrast to transurethral resection of the prostate, which requires a similar procedure to transurethral resection of bladder tumors, holmium laser enucleation of the prostate requires a special surgical technique: enucleation and morcellation with around 10 years’ history of experience, even in Japan. The present review introduces the current status of holmium laser enucleation of the prostate, so that it surely contributes to the knowledge of International Journal of Urology readers who could be experienced surgeons or beginners as well.     

Bleeding after holmium laser enucleation of the prostate: Lessons learned the hard way

Study Type – Therapy (case series)
Level of Evidence 4 What’s known on the subject? and What does the study add? Holmium laser enucleation of the prostate is rapidly gaining popularity as an alternative and in some institutions a replacement for standard transurethral resection of the prostate. It has been proven to have at least equivalent outcomes to the TURP and noted to be exceptionally hemostatic. This study shares some caveats regarding bleeding after HoLEP.

OBJECTIVE

To examine specific causes of postoperative bleeding requiring transfusion after holmium laser enucleation of the prostate (HoLEP) in order to enhance preoperative screening and counseling.

MATERIALS AND METHODS

After Institutional Review Board (IRB) approval, a retrospective review of a single surgeon’s experience of 130 consecutive HoLEPs was performed to specifically examine patients requiring perioperative blood transfusions. All patients from August 2007 to April 2009 who underwent a HoLEP at our institution since its inception were included. These patients’ charts were reviewed to gain insight into their bleeding diathesis. A case series report was compiled and compared with the relevant published literature.

RESULTS

Of the 130 patients, eight (6.7%) were found to require transfusion postoperatively. Four of these patients required a second operation for completion. These patients had a variety of causes for increased bleeding and subsequent transfusion including: chronic anticoagulation (n = 1), significant cardiac disease requiring maintenance of hemoglobin (n = 4), sepsis with secondary disseminated intravascular coagulation (n = 1), large prostate size (>150 g) (n = 4), underlying prostate cancer (n = 1) and inadequate anesthesia during the procedure leading to patient movement (n = 1). All patients made a full recovery with satisfactory urinary symptom improvement except for one patient with residual incontinence at last follow‐up.

CONCLUSIONS

Despite the many benefits of holmium laser enucleation, all patients should be counseled regarding the real potential for postoperative blood transfusion. When feasible, any known bleeding risk should be minimized by the surgeon as long it is done safely for the benefit of the patient considering their co‐morbidities.     

经尿道大功率钬激光前列腺剜除术(HoEAP)

目的　经尿道前列腺钬激光剜除、前列腺组织粉碎术的疗效评价。　方法　自 2 0 0 1年 8月起应用 10 0W钬激光器以及组织粉碎器对 82例前列腺增生进行经尿道前列腺的钬激光剜除与前列腺组织粉碎。　结果全部病例手术顺利 ,手术切除时间 :(2 5～ 68)分钟 ,被切下的前列腺组织 (2 5～ 76)克。平均 5 9.5克 ,组织粉碎时间 :(2 0～ 90 )分钟 ,术后留置尿管 16小时～ 96小时 ,平均 3 6小时 ,拔管即恢复排尿。随防 2月～ 2 8月 ,平均 5月 ,I-PSS评分达优 5 4例(65 .8% )、良 16例 (19.5 % )、中 12例 (14 .6% )。无严重并发症。　结论　钬激光剜除前列腺技术 ,切割精确 ,安全快捷 ,出血少 ,组织粉碎技术可靠 ,速度快 ,术后患者排尿畅通     

Influence of prostate size on the outcome of holmium laser enucleation of the prostate

OBJECTIVE

To analyse the effect of prostate size on the outcome of holmium laser enucleation of prostate (HoLEP, an established procedure for treating symptomatic benign prostatic hypertrophy, BPH), in the initial 354 patients at 1 year of follow‐up.

PATIENTS AND METHODS

We retrospectively reviewed the records of 354 patients who had HoLEP at our institution from April 2003 to March 2007. In 235 patients the prostate weighed <60 g (group 1), in 77 it weighed 60–100 g (group 2) and in 42 >100 g (group 3). Demographic data and perioperative variables were recorded and compared among the three groups.

RESULTS

The mean prostate size was 38.1, 76.4 and 133.5 g for groups 1, 2 and 3, respectively (P < 0.001), and the respective mean weight of resected prostate was 18.47, 40.8 and 82.76 g, respectively (P < 0.001). The mean procedure efficiency increased from 0.36 g/min in group 1 to 0.49 g/min in group 2 and 0.58 g/min in group 3 (P < 0.001). The decrease in haemoglobin level after HoLEP was greater in group 3 than in the other groups. Overall, HoLEP resulted in a 75% reduction in American Urologic Association symptom score, a 225% increase in peak urinary flow rate and an 86% decrease in postvoid residual urine volume at 1 year of follow‐up. Perioperative complications were evenly distributed among the three groups, except for a higher incidence of superficial bladder mucosal injury and stenotic complications in group 3.

CONCLUSIONS

HoLEP is a safe and effective procedure for treating symptomatic BPH, independent of prostate size, and is associated with low morbidity. The efficiency of HoLEP increases with increasing prostate size.     

Understanding holmium laser enucleation of the prostate (HoLEP) recovery: Assessing patient expectations and understanding

IntroductionAlthough holmium laser enucleation of the prostate (HoLEP) is a highly effective surgery, there is a variable recovery period where patients may experience hematuria, dysuria, or urinary incontinence (UI). Despite preoperative consultation, there is a paucity of literature examining the effectiveness of physician-patient communication in preparing the patient for the postoperative recovery period. We sought to examine recovery expectations as a patient-reported outcome (PRO) metric for HoLEP.MethodsWith institutional review board approval, we queried our electronic medical record and retrospective clinical registry to identify 50 consecutive patients that underwent HoLEP from November 2019 to March 2020 by two endourologists. Patients were provided questionnaires via Twistle^© ≥6 months postoperatively. Patient demographics and perioperative course was examined in the context of responses. Our primary objective was determining whether patients felt they had a reasonable understanding of the recovery process.ResultsWe observed a 92% (46/50) response rate, with an average patient age of 69.4 years (range 55–88). Overall, 91.3% (42/46) felt they had a reasonable understanding of the recovery. Additionally, 97.8% (45/46) were aware of temporary UI, with 87% having ≥1 episodes of UI after catheter removal. We found 47.8% (22/46) of patients expected UI to resolve within 30 days, while 8.6% expected >90 days of UI. All patients were aware of the risk of hematuria, with 93.5% (43/46) expecting resolution within 30 days (<7 days: 47.8%; 7–14 days: 28.3%; 15–30 days: 17.4%).ConclusionsAlthough surgical technique continues to improve HoLEP, ensuring adequate physician-patient communication to optimize expectations is crucial. We report patient understanding of HoLEP recovery and areas for future improvement.     

钬激光与铥激光前列腺剜除术对勃起功能的影响

近年来钬激光与铥激光前列腺剜除术被广泛地应用于临床,其显著的疗效、较好的安全性以及较低的并发症发生率均已被证实。随着生活水平的提高,患者对于BPH的治疗已经不仅仅满足于下尿路症状的改善。这两种术式对男性性功能尤其是勃起功能的影响越来越受到重视,而相关研究并不是很多,且不同的研究之间也存在着一定的争议。大部分观点认为,这两种术式不影响患者勃起功能。也有一些研究表明少数患者术前勃起功能正常,术后出现了一定程度的勃起功能下降。虽然患者对勃起功能障碍的关注不多,但是心理因素也可能是影响勃起功能的一个重要因素,术前应当和患者充分沟通,了解手术对性功能产生不良影响的风险程度。本文就近年来发表的有关钬激光与铥激光前列腺剜除术对勃起功能影响的文献做一综述。